Cargando…
Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022
Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (To...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622230/ https://www.ncbi.nlm.nih.gov/pubmed/36198306 http://dx.doi.org/10.3201/eid2811.221127 |
_version_ | 1784821714554716160 |
---|---|
author | Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Okuda, Moe Ujie, Michiko Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Hamabata, Taiki Ito, Mutsumi Chiba, Shiho Kobayashi, Ryo Takahashi, Satoshi Mitamura, Keiko Hagihara, Masao Shibata, Akimichi Uwamino, Yoshifumi Hasegawa, Naoki Ebina, Toshiaki Izumi, Akihiko Kato, Hideaki Nakajima, Hideaki Sugaya, Norio Seki, Yuki Iqbal, Asef Kamimaki, Isamu Yamazaki, Masahiko Kawaoka, Yoshihiro Furuse, Yuki |
author_facet | Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Okuda, Moe Ujie, Michiko Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Hamabata, Taiki Ito, Mutsumi Chiba, Shiho Kobayashi, Ryo Takahashi, Satoshi Mitamura, Keiko Hagihara, Masao Shibata, Akimichi Uwamino, Yoshifumi Hasegawa, Naoki Ebina, Toshiaki Izumi, Akihiko Kato, Hideaki Nakajima, Hideaki Sugaya, Norio Seki, Yuki Iqbal, Asef Kamimaki, Isamu Yamazaki, Masahiko Kawaoka, Yoshihiro Furuse, Yuki |
author_sort | Yamayoshi, Seiya |
collection | PubMed |
description | Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (Tokyo Metropolitan Area and Hokkaido Prefecture) during February 2020–March 2022. The results showed that ≈3.8% of the population had become seropositive by January 2021. The seroprevalence increased with the administration of vaccinations; however, among the elderly, seroprevalence was not as high as the vaccination rate. Among children, who were not eligible for vaccination, infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants. Nevertheless, seroprevalence for unvaccinated children <5 years of age was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level. |
format | Online Article Text |
id | pubmed-9622230 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-96222302022-11-05 Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Okuda, Moe Ujie, Michiko Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Hamabata, Taiki Ito, Mutsumi Chiba, Shiho Kobayashi, Ryo Takahashi, Satoshi Mitamura, Keiko Hagihara, Masao Shibata, Akimichi Uwamino, Yoshifumi Hasegawa, Naoki Ebina, Toshiaki Izumi, Akihiko Kato, Hideaki Nakajima, Hideaki Sugaya, Norio Seki, Yuki Iqbal, Asef Kamimaki, Isamu Yamazaki, Masahiko Kawaoka, Yoshihiro Furuse, Yuki Emerg Infect Dis Research Japan has reported a relatively small number of COVID-19 cases. Because not all infected persons receive diagnostic tests for COVID-19, the reported number must be lower than the actual number of infections. We assessed SARS-CoV-2 seroprevalence by analyzing >60,000 samples collected in Japan (Tokyo Metropolitan Area and Hokkaido Prefecture) during February 2020–March 2022. The results showed that ≈3.8% of the population had become seropositive by January 2021. The seroprevalence increased with the administration of vaccinations; however, among the elderly, seroprevalence was not as high as the vaccination rate. Among children, who were not eligible for vaccination, infection was spread during the epidemic waves caused by the SARS-CoV-2 Delta and Omicron variants. Nevertheless, seroprevalence for unvaccinated children <5 years of age was as low as 10% as of March 2022. Our study underscores the low incidence of SARS-CoV-2 infection in Japan and the effects of vaccination on immunity at the population level. Centers for Disease Control and Prevention 2022-11 /pmc/articles/PMC9622230/ /pubmed/36198306 http://dx.doi.org/10.3201/eid2811.221127 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Yamayoshi, Seiya Iwatsuki-Horimoto, Kiyoko Okuda, Moe Ujie, Michiko Yasuhara, Atsuhiro Murakami, Jurika Duong, Calvin Hamabata, Taiki Ito, Mutsumi Chiba, Shiho Kobayashi, Ryo Takahashi, Satoshi Mitamura, Keiko Hagihara, Masao Shibata, Akimichi Uwamino, Yoshifumi Hasegawa, Naoki Ebina, Toshiaki Izumi, Akihiko Kato, Hideaki Nakajima, Hideaki Sugaya, Norio Seki, Yuki Iqbal, Asef Kamimaki, Isamu Yamazaki, Masahiko Kawaoka, Yoshihiro Furuse, Yuki Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 |
title | Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 |
title_full | Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 |
title_fullStr | Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 |
title_full_unstemmed | Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 |
title_short | Age-Stratified Seroprevalence of SARS-CoV-2 Antibodies before and during the Vaccination Era, Japan, February 2020–March 2022 |
title_sort | age-stratified seroprevalence of sars-cov-2 antibodies before and during the vaccination era, japan, february 2020–march 2022 |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622230/ https://www.ncbi.nlm.nih.gov/pubmed/36198306 http://dx.doi.org/10.3201/eid2811.221127 |
work_keys_str_mv | AT yamayoshiseiya agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT iwatsukihorimotokiyoko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT okudamoe agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT ujiemichiko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT yasuharaatsuhiro agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT murakamijurika agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT duongcalvin agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT hamabatataiki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT itomutsumi agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT chibashiho agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT kobayashiryo agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT takahashisatoshi agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT mitamurakeiko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT hagiharamasao agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT shibataakimichi agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT uwaminoyoshifumi agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT hasegawanaoki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT ebinatoshiaki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT izumiakihiko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT katohideaki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT nakajimahideaki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT sugayanorio agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT sekiyuki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT iqbalasef agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT kamimakiisamu agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT yamazakimasahiko agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT kawaokayoshihiro agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 AT furuseyuki agestratifiedseroprevalenceofsarscov2antibodiesbeforeandduringthevaccinationerajapanfebruary2020march2022 |